112529-15-4 Usage
Description
Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of non-insulin dependent diabetes mellitus
(NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester
into thiazolidine with thiourea. As with other representatives in this
class, it potently activates the nuclear receptor peroxisome proliferator-activated
receptor gamma which is believed to be involved in the regulation of insulin
resistance and adipogenesis. In several obese and obese diabetic animal
models, treatment with Pioglitazone resulted in reductions in plasma glucose
and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs or insulin, was shown
to significantly improve glycemic control in type-2 diabetes and demonstrated a
beneficial effect on insulin resistance and other clinically relevant parameters as
plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be
safe and well tolerated and is said to have a lower occurrence of hepatic toxicity
as well as a low probability for drug interaction.
Chemical Properties
Colourless Prisms
Originator
Takeda (Japan)
Uses
Different sources of media describe the Uses of 112529-15-4 differently. You can refer to the following data:
1. euglycemic agent
2. Pioglitazone Hydrochloride is used as an antidiabetic.
3. Pioglitazone hydrochloride is a euglycemic agent,used as an antidiabetic.
Therapeutic Function
Antidiabetic
General Description
Pioglitazone hydrochloride is an oral antidiabetic agent used in the treatment of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes.
Biochem/physiol Actions
Selective PPARγ agonist
References
1) Merck 14:7452
2) Sakamoto et al. (2000), Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone; Biochem. Biophys. Res. Commun., 278 704
3) Wilson et al. (2000), The PPARs: From Orphan Receptors to Drug Discovery; J. Med. Chem., 43 527
4) Shannon et al. (2017), Pioglitazone Inhibits Mitochondrial Pyruvate Metabolism and Glucose Production in Hepatocytes; FEBS J., 284 451
5) Zhao et al. (2016), The Antidepressant-Like Effects of Pioglitazone in a Chronic Mild Stress Mouse Model Are Associated With PPARγ-Mediated Alteration of Microglial Activation Phenotypes; Neuroinflamm., 13 259
Check Digit Verification of cas no
The CAS Registry Mumber 112529-15-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,5,2 and 9 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 112529-15:
(8*1)+(7*1)+(6*2)+(5*5)+(4*2)+(3*9)+(2*1)+(1*5)=94
94 % 10 = 4
So 112529-15-4 is a valid CAS Registry Number.
InChI:InChI=1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
112529-15-4Relevant articles and documents
NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES
-
Page/Page column 0202-0203, (2014/04/03)
A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.
A PROCESS FOR THE PREPARATION OF 4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]NITROBENZENE AND PIOGLITAZONE
-
Page/Page column 8, (2009/12/05)
A process for the preparation of 4-[2-(5-ethyl-2-pyridyi)ethoxy]nitrobenzene is described, which comprises the step of reacting 2-(5-ethyl-2-pyridyl)ethanol with 1-fluoro-4-nitrobenzene in acetone in the presence of an alkali metal hydroxide. The intermediate 4-[2-(5-ethyl-2-pyridyI)ethoxy]nitrobenzene is used for the preparation of pioglitazone.
NOVEL PROCESS FOR THE SYNTHESIS OF PIOGLITAZONE AND ITS SALTS THEREOF
-
Page/Page column 7, (2009/01/20)
Present invention relates to an improved process for the preparation of thiazolidinedione derivatives. Further the invention provides the hydrogenation of acid addition salt of benzylidene compound with less reducing agent under low Hydrogen gas pressure to get substantially pure thiazolidinedione derivatives with improved yields.